Literature DB >> 12511175

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

Herbert Y Meltzer1, Larry Alphs, Alan I Green, A Carlo Altamura, Ravi Anand, Alberto Bertoldi, Marc Bourgeois, Guy Chouinard, M Zahur Islam, John Kane, Ranga Krishnan, J P Lindenmayer, Steven Potkin.   

Abstract

BACKGROUND: Approximately 50% of patients with schizophrenia or schizoaffective disorder attempt suicide, and approximately 10% die of suicide. Study results suggest that clozapine therapy significantly reduces suicidal behavior in these patients.
METHODS: A multicenter, randomized, international, 2-year study comparing the risk for suicidal behavior in patients treated with clozapine vs olanzapine was conducted in 980 patients with schizophrenia or schizoaffective disorder, 26.8% of whom were refractory to previous treatment, who were considered at high risk for suicide because of previous suicide attempts or current suicidal ideation. To equalize clinical contact across treatments, all patients were seen weekly for 6 months and then biweekly for 18 months. Subsequent to randomization, unmasked clinicians at each site could make any interventions necessary to prevent the occurrence of suicide attempts. Suicidal behavior was assessed at each visit. Primary end points included suicide attempts (including those that led to death), hospitalizations to prevent suicide, and a rating of "much worsening of suicidality" from baseline. Masked raters, including an independent suicide monitoring board, determined when end point criteria were achieved.
RESULTS: Suicidal behavior was significantly less in patients treated with clozapine vs olanzapine (hazard ratio, 0.76; 95% confidence interval, 0.58-0.97; P =.03). Fewer clozapine-treated patients attempted suicide (34 vs 55; P =.03), required hospitalizations (82 vs 107; P =.05) or rescue interventions (118 vs 155; P =.01) to prevent suicide, or required concomitant treatment with antidepressants (221 vs 258; P =.01) or anxiolytics or soporifics (301 vs 331; P =.03). Overall, few of these high-risk patients died of suicide during the study (5 clozapine vs 3 olanzapine-treated patients; P =.73).
CONCLUSIONS: Clozapine therapy demonstrated superiority to olanzapine therapy in preventing suicide attempts in patients with schizophrenia and schizoaffective disorder at high risk for suicide. Use of clozapine in this population should lead to a significant reduction in suicidal behavior.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12511175     DOI: 10.1001/archpsyc.60.1.82

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  244 in total

Review 1.  Management of schizophrenia in children and adolescents: focus on pharmacotherapy.

Authors:  Gabriele Masi; Francesca Liboni
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

Review 2.  Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned?

Authors:  Robert D Gibbons; J John Mann
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

3.  Does lithium save lives?

Authors:  Russell T Joffe
Journal:  J Psychiatry Neurosci       Date:  2004-01       Impact factor: 6.186

Review 4.  Dose response and atypical antipsychotics in schizophrenia.

Authors:  Bruce J Kinon; Jonna Ahl; Virginia L Stauffer; Angela L Hill; Peter F Buckley
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 5.  Bipolar disorder and schizophrenia: convergent molecular data.

Authors:  Wade Berrettini
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

6.  The ultimate endpoint.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2012-02-06       Impact factor: 53.440

7.  Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia.

Authors:  A P Rajkumar; B Poonkuzhali; A Kuruvilla; A Srivastava; M Jacob; K S Jacob
Journal:  Psychopharmacology (Berl)       Date:  2012-06-15       Impact factor: 4.530

Review 8.  Suicide and suicidal behaviour.

Authors:  Gustavo Turecki; David A Brent
Journal:  Lancet       Date:  2015-09-15       Impact factor: 79.321

9.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

10.  [Causes, diagnosis and treatment of suicidality].

Authors:  D Althaus; U Hegerl
Journal:  Nervenarzt       Date:  2004-11       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.